Investor Presentaiton
The Biocon Journey: A Continuous Evolution
THE
An
1978-
1999
Enzymes
Company
2005-
2010-
2016-
2019 &
00-000
2000-
2004
Transforming
into a
Biopharma
Company
Successful IPO,
Biocon listed in
India (2004)
2009
Building the Base
Business and
Expertise in
Biologics
Enzymes Business
Divested (2007)
Global
2015
Strategic Global
Alliance with
Mylan for
Biosimilars
Expanded (2013)
Generic
Formulations
Development of
Biosimilars in
Partnership with
Mylan (2009)
Business Unit set
up (2013)
IPO of Syngene
(2015)
2018
Commercialized
Biosimilars for
Diabetes &
Cancer in
Japan, U.S., EU
Global
Partnership with
Sandoz for Next-
Gen Biosimilars
(2018)
Beyond
Poised for
Global Impact
with
Biosimilars
Investments in
complex
Generic
Formulations
$
Biocon
Touching a billion
lives through
affordable innovation
Unwavering focus through the years on innovation & difficult to make, niche products to create
tangible differentiators for sustainable growth
5View entire presentation